Tesamorelin and Deep Belly Fat: What Three Clinical Studies Found
Not all belly fat is the same. One layer sits just under the skin. Doctors call this subcutaneous fat. Another layer sits deeper inside the abdomen, around the liver, gut and other organs. This is visceral fat.
Researchers pay close attention to visceral fat. Studies link it strongly with problems in how the body handles blood sugar and blood fats, and with heart and blood vessel health [2].
Tesamorelin is a peptide that researchers have tested against this deeper fat. Below is what three clinical studies found, explained in plain language.
A signal, not a hormone
Growth hormone (GH) is made by the pituitary, a small gland at the base of the brain. The body does not release it in a steady stream. It comes in bursts, or "pulses." A brain signal called growth hormone-releasing hormone (GHRH) tells the pituitary when to release each pulse.
Tesamorelin is a lab-made version of GHRH. It does not replace growth hormone. Instead, it asks the pituitary to make more of its own.
A small study in 13 healthy men tested this idea over two weeks [1]. Researchers sampled blood every 10 minutes through the night. Overnight growth hormone levels rose. The rise came from larger pulses and a higher baseline level, while the number of pulses stayed about the same [1]. IGF-1, a marker the liver makes in response to growth hormone, also rose. Two weeks after stopping, these levels had returned to where they started [1].
The same study noticed something else. At the start, men with more visceral fat tended to have lower growth hormone output [1]. This fits a broader idea in the research: excess deep belly fat and a quieter growth hormone rhythm often go together.
The authors also point out a design feature. Because tesamorelin works through the pituitary, the body's own feedback system stays in place. When IGF-1 rises, it can still tell the pituitary to slow down [1].
What happened to deep belly fat
The most direct test came from a year-long trial in 60 adults with abdominal obesity and lower-than-expected growth hormone output [2]. It was randomized and double-blind. That means people were assigned by chance to tesamorelin or a placebo (a dummy injection), and neither they nor the researchers knew who got which.
Visceral fat was measured with CT scans. Over 12 months, visceral fat went down in the tesamorelin group and up in the placebo group. The net difference between the groups was about 19% [2].
Three other findings stand out:
The effect was selective. Fat under the skin did not change in a meaningful way. The loss was mainly in the deeper fat [2].
Body weight stayed about the same, yet waist size fell by around 3 cm compared with placebo. Lean body mass went up slightly while fat mass went down [2].
The change held. Results at 6 months and 12 months were similar [2].
Markers linked to heart health
The same trial looked at several markers that doctors use to read cardiovascular risk [2].
Triglycerides, a type of fat in the blood, fell by about 20% compared with placebo. C-reactive protein (CRP), a marker of low-grade inflammation, also went down [2].
The researchers also used ultrasound to measure carotid intima-media thickness. This is the thickness of the inner layers of the main neck artery, and it tends to increase over time. In the tesamorelin group it became slightly thinner, with a net difference of about 6% compared with placebo [2]. The authors say more studies are needed to know what this change means for long-term heart health [2].
Fasting blood sugar, sugar levels after a glucose drink, and HbA1c (a three-month average of blood sugar) did not differ between groups in this trial [2].
What about liver fat?
A third study looked at the liver. It was a six-month randomized, placebo-controlled trial in about 50 people living with HIV who had built up abdominal fat [3]. In this group, deep belly fat often travels together with fat inside the liver [3].
Visceral fat fell again, by about 17% more than placebo [3]. Liver fat, measured with a special type of MRI scan, also went down. The authors describe the drop as modest, and they say its clinical importance is not yet known [3]. The change in liver fat tracked with the change in visceral fat, and it happened without a change in body weight [3].
This is an encouraging hint that reducing deep belly fat may also ease fat build-up in the liver. It still needs testing in wider groups of people.
To learn more about how this peptide is used in practice, see our tesamorelin page and the wider peptides overview.
What the evidence can and cannot tell us
These studies are well designed, but they are small. The largest had 60 people, and only about six in ten finished the full year [2]. The liver study was done only in people with HIV [3]. The two-week study was in men only [1]. Results may not apply in the same way to everyone.
The trials were also limited in time. In the liver study, the authors note that earlier research found visceral fat may return after treatment stops [3]. In the six-month study, blood sugar rose briefly in the first two weeks and then settled, and HbA1c rose slightly over six months [3]. In the one-year trial, a few people needed a lower dose because their IGF-1 rose above the normal range for their age [2].
Questions to talk through with your doctor
Before starting tesamorelin, it helps to go over a few points with your doctor:
Your health history. The trials did not include people with active cancer or a past history of certain cancers, pituitary conditions, diabetes, or pregnancy [2,3].
A starting baseline. Your doctor may want to check blood sugar and IGF-1 before you begin and at intervals after.
Your other medicines. Share everything you take, including supplements and other peptides.
The plan. Your doctor sets the dose and decides how long to continue.
The bigger picture. Ask how nutrition, sleep and exercise fit alongside any treatment plan.
Last reviewed: 9 November 2026
References
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8. doi:10.1210/jc.2010-1587
Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-79. doi:10.1210/jc.2012-2794
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on liver fat and visceral fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. doi:10.1001/jama.2014.8334

Comments